Mannkind

Summer Street must have missed this part of the call:

.

.

In summary, the 171 trial met the primary efficacy endpoint of non-inferior reduction in A1c when comparing AFREZZA -Gen2 to insulin aspart as well as the primary safety endpoint of showing a comparable mean change in FEV1 over the treatment period between the Gen2 and the MedTone treatment groups.